Swedish Orphan Biovitrum AB (publ) Q3 2025 Earnings Call Transcript - Thomson StreetEvents

Swedish Orphan Biovitrum AB (publ) Q3 2025 Earnings Call Transcript

Swedish Orphan Biovitrum AB (publ) Q3 2025 Earnings Call Transcript - Thomson StreetEvents
Swedish Orphan Biovitrum AB (publ) Q3 2025 Earnings Call Transcript
Published Oct 20, 2025
13 pages (8778 words) — Published Oct 20, 2025
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of SOBIV.ST earnings conference call or presentation 20-Oct-25 11:00am GMT

  
Brief Excerpt:

...Thank you, and hello, everyone. I'm really delighted, and we are overall delighted to welcome you to the third quarter 2025 conference for investors and analysts. As usual, we posted the presentation beforehand. As far as the next slide is concerned, the disclaimer, we would like to remind you of the usual provisions on statement about expectations and projections of future events. And unless stated otherwise, we will be making comments that most relate to the third quarter at constant currency rates in Swedish krona. Today, we plan to cover the following key aspects of our Q3 report. I'm joined by Henrik Stenqvist, our CFO; and Lydia Abad-Franch, Head of R&D and Chief Medical Officer. We plan to review the presentations first and then open up for Q&A at around -- until or around 2:00 PM. (Conference Instructions) So with this said, let's go straight to the presentation. As we want to cover quite a few topics today on the quarter, I would like to provide you with an overview before driving...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Swedish Orphan Biovitrum AB (publ)
Ticker
SOBIV.ST
Time
11:00am GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Viktor Sundberg - Nordea Markets - Analyst : So first one on the Gamifant. It's quite a pickup in sales here in Q3, and you referred to some impact from your extended approval into Macrophage Activation in Still's disease. So I was just wondering, was this a major driver here? Or was it other factors? And just in general, also how the initial uptake is for this indication? And then I also have a second one on Gamifant, but I can start here.

Question: Viktor Sundberg - Nordea Markets - Analyst : Okay. Great. And also another one here on Gamifant. As you mentioned, we have the EMBRACE trial coming up. And I guess sepsis is still quite a heterogeneous patient population if you account for your biomarker selection with comorbidities, et cetera. So I just wanted to understand your thinking if results show trends, but not statistically significant benefits on the SOFA score. Would you still jump into a Phase 3? And do you see this trial as more of a chance of getting important data points for moving the program further? And maybe on the other hand, if the results are very, very robust, what's your thinking here of using accelerated approval in that case? Just trying to understand what outcomes that are on the table for this readout. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 20, 2025 / 11:00AM, SOBIV.ST - Q3 2025 Swedish Orphan Biovitrum AB (publ) Earnings Call

Question: Henrietta Boeg - Deutsche Bank AG - Analyst : Just one on what extent can we extrapolate the 2025 margin performance exceeding expectations? And if you could talk about the margin outlook over the coming years, given the need to invest behind the gout and the C3G launches, that would be helpful. And then I guess just a follow-up on the sepsis data in Q4, so we'd have to wait until a follow-up, maybe 2026 for the Phase 3 details?

Table Of Contents

Swedish Orphan Biovitrum AB (publ) to Acquire Arthrosi Therapeutics Call Transcript – 2025-12-15 – US$ 54.00 – Edited Transcript of SOBIV.ST M&A conference call or presentation 15-Dec-25 7:00am GMT

Swedish Orphan Biovitrum AB (publ) NASP and Uncontrolled Gout Call Transcript – 2025-09-16 – US$ 54.00 – Edited Transcript of SOBIV.ST conference call or presentation 16-Sep-25 2:30pm GMT

Swedish Orphan Biovitrum AB (publ) Q2 2025 Earnings Call Transcript – 2025-07-16 – US$ 54.00 – Edited Transcript of SOBIV.ST earnings conference call or presentation 16-Jul-25 12:00pm GMT

Swedish Orphan Biovitrum AB (publ) Q1 2025 Earnings Call Transcript – 2025-04-29 – US$ 54.00 – Edited Transcript of SOBIV.ST earnings conference call or presentation 29-Apr-25 1:30pm GMT

Swedish Orphan Biovitrum AB (publ) Q4 2024 Earnings Call Transcript – 2025-02-05 – US$ 54.00 – Edited Transcript of SOBIV.ST earnings conference call or presentation 5-Feb-25 1:30pm GMT

Swedish Orphan Biovitrum AB (publ) Q3 2024 Earnings Call Transcript – 2024-10-24 – US$ 54.00 – Edited Transcript of SOBIV.ST earnings conference call or presentation 24-Oct-24 12:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Swedish Orphan Biovitrum AB (publ) Q3 2025 Earnings Call Transcript" Oct 20, 2025. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2025-Swedish-Orphan-Biovitrum-AB-publ-Earnings-Call-T16526559>
  
APA:
Thomson StreetEvents. (2025). Swedish Orphan Biovitrum AB (publ) Q3 2025 Earnings Call Transcript Oct 20, 2025. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q3-2025-Swedish-Orphan-Biovitrum-AB-publ-Earnings-Call-T16526559>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.